» Articles » PMID: 1290402

Single-dose Toxicokinetics of Aluminum in the Rat

Overview
Journal Arch Toxicol
Specialty Toxicology
Date 1992 Jan 1
PMID 1290402
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The toxicokinetics of aluminum (Al) in male Wistar rats was studied after single intragastric (IG) doses of 1000 and 12,000 micrograms Al/kg and intravenous (IV) doses of 10, 100, 1000, and 12,000 micrograms Al/kg. Serial blood samples, daily samples of urine and feces as well as brain, liver, kidney, spleen, quadriceps muscle, and femur samples were collected. Al was measured by atomic absorption spectrometry. Al blood profiles after IV doses were adequately described by a two-compartment open model. Al toxicokinetics was dose dependent and appeared to plateau at 12,000 micrograms/kg. At IV doses between 10 and 1000 micrograms/kg the terminal half-life of elimination from whole blood (t1/2 beta) increased from 29.9 +/- 7.8 to 209.3 +/- 32.6 min, and the total body clearance (CL) decreased from 2.45 +/- 0.64 to 0.28 +/- 0.03 ml min-1 kg-1. Following an IV bolus of 10 and 100 micrograms/kg the administered Al was recovered completely from urine (94.4% +/- 9.9% and 98.5% +/- 3.2%). Twenty-nine days after the IV dose of 1000 micrograms/kg daily renal excretion decreased to baseline values while only 55.1% +/- 8.0% of the dose was excreted. Nineteen days after the single IV dose of 1000 micrograms/kg Al accumulated in liver (28.1 +/- 7.7 versus 1.7 +/- 0.5 micrograms/g of control rats) and spleen (72.5 +/- 21.1 versus < 0.4 microgram/g). After the single 1000 micrograms/kg IG dose no absorption of Al was detectable. The IG dose of 12,000 micrograms/kg resulted in a maximum blood Al level of 47.9 +/- 12.4 micrograms/l after 50 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Physiology-based toxicokinetic modelling of aluminium in rat and man.

Hethey C, Hartung N, Wangorsch G, Weisser K, Huisinga W Arch Toxicol. 2021; 95(9):2977-3000.

PMID: 34390355 PMC: 8380244. DOI: 10.1007/s00204-021-03107-y.


Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Krewski D, Yokel R, Nieboer E, Borchelt D, Cohen J, Harry J J Toxicol Environ Health B Crit Rev. 2007; 10 Suppl 1:1-269.

PMID: 18085482 PMC: 2782734. DOI: 10.1080/10937400701597766.

References
1.
Bishop N, Robinson M, Lendon M, Hewitt C, Day J, Ohara M . Increased concentration of aluminium in the brain of a parenterally fed preterm infant. Arch Dis Child. 1989; 64(9):1316-7. PMC: 1792721. DOI: 10.1136/adc.64.9.1316. View

2.
Pai S, Melethil S . Kinetics of aluminum in rats I: Dose-dependent elimination from blood after intravenous administration. J Pharm Sci. 1989; 78(3):200-2. DOI: 10.1002/jps.2600780305. View

3.
ZUMKLEY H, Bertram H, Brandt M, Roedig M, Spieker S, Kisters K . [Aluminum concentration in the bones and brain following the administration of antacids]. Fortschr Med Suppl. 1987; 19:15-8. View

4.
Wilhelm M, Sprenger K, Vossas U, OHNESORGE F . Aluminum load in chronic intermittent plasma exchange. J Toxicol Clin Toxicol. 1987; 25(3):209-20. DOI: 10.3109/15563658708992625. View

5.
Henry D, Goodman W, Nudelman R, DiDomenico N, Alfrey A, Slatopolsky E . Parenteral aluminum administration in the dog: I. Plasma kinetics, tissue levels, calcium metabolism, and parathyroid hormone. Kidney Int. 1984; 25(2):362-9. DOI: 10.1038/ki.1984.25. View